ObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of ObsEva (NASDAQ:OBSVGet Free Report) in a research report issued on Tuesday. The brokerage set a “hold” rating on the stock.

ObsEva Price Performance

ObsEva has a 12 month low of $0.08 and a 12 month high of $2.14. The stock has a market capitalization of $7.94 million, a PE ratio of -0.11 and a beta of 0.68. The firm has a 50-day moving average price of $0.01.

About ObsEva

(Get Free Report)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and AndrĂ© Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Featured Stories

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.